Testicular tumor markers: Corner-stones in the management of malignant germ cell tumors

LaboratoriumsMedizin

Volumn 28, Issue 2, 2004, Pages 109-115

  Albrecht, Walter ^a,d   De Santis, Maria ^b   Dossenbach Glaningers, Astrid ^c  

^a Rudolfstiftung   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Urologische Universitatsklinik   (Austria)

Author keywords

AFP; HCG; LDH; PLAR; Testicular cancer; Tumor marker

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; GERM CELL TUMOR; HUMAN; LABORATORY TEST; METASTASIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; TESTIS TUMOR;

EID: 2442486515     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2004.018     Document Type: Article

References (39)

1. th edition, New York. 1997.
2. th edition, Berlin: Springer 2002;176-180.
3. Lamerz R, Albrecht W, Bialk P, Dati F, Duffy MJ, Gerl A, Greiner-Mai E, Malbohan I, Schmid HP, Semjonow A, Stieber P, Van Poppel H. Tumour markers in germ cell cancer: EGTM recommendations. Anticancer Res 1999;19:2795-2798.
4. See WA, Cohen MB, Hoxie LD. Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity. Cancer 1993;71:2048-2054.
5. Ockhuizen T, Veenstra J, Suurmeijer AJH, Fleuren GJ, Schraffordt Koops H, de Bruijn HW, Sleijfer DT. Protein composition of cyst fluid from mature teratoma in patients with nonseminomatous germ cell tumours of the testis. Cancer 1985;56:2264-2268.
6. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707.
7. Mann K. Tumor markers in testicular cancers. Urologe A 1990;29:77-86.
8. Doherty AP, Bower M, Christmas TJ. The role of tumor markers in the diagnosis and treatment of testicular germ cell cancers. Br J Urol 1997;79:247-252.
9. Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 1992;69:286-290.
10. Von Eyben FE. A systematic review of lactate dehydrogenase isoenzyme I and germ cell tumors. Clin Biochem 2001;34:441-454.
11. von Eyben FE, de Graaff WE, Marrink J, Blaabjerg O, Sleijfer DT, Koops HS, Oosterhuis JW, Petersen PH, van Echten-Arends J, de Jong B. Serum lactate dehydrogenase isoenzyme-1 activity in patients with testicular germ-cell tumours correlates with the total number of copies of the short arm of chromosome 12 in the tumour. Mol Gen Genet 1991;235:140-146.
12. Albrecht W, Bonner E, Jeschke K, Stoiber F, Schmidt PR, Scheiber K, Kozak W, De Santis M, Schwarzmaier A and the Austrian Uro-Oncology Group. PLAP as a marker for germ cell tumours. In Jones WG, Appleyard P, Harnden P et al (eds.) Germ cell tumours IV. London: John Libbey &Co 1998;105-109.
13. Nielsen OS, Munro AJ, Duncan W, Sturgeon J, Gospodarowicz MK, Jewett MA, Malkin A, Thomas GM. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma? Eur J Cancer 1990;26:1049-1054.
14. Koshida K, Uchibayashi T, Yamamoto H, Hirano K. Significance of placental alkaline phosphatase (PIAP) in the monitoring of patients with seminoma. Br J Urol 1996;77:138-142.
15. Lamerz R. Alpha-Fetoprotein. In: Thomas L (ed). Clinical Laboratory Diagnostics, TH-Books Verlagsgesellschaft, Frankfurt am Main 1998;941-945.
16. Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT. Ectopic production of human chorionic gonadotropin by neoplasms. Ann Intern Med 1973;78:39-45.
17. Staples J. Alpha-fetoprotein, cancer, and benign conditions. Lancet 1986;2:1277.
18. Hogan P, Sharpe M, Smedley H, Sikora K.: Cannabinoids and HCG levels in patients with testicular cancer. Lancet 1983;2:1144.
19. Schefer H, Mattmann S, Joss RA. Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. Ann Oncol 1998;9:667-672.
20. Johnson PJ, Ho S, Cheng P, Chan A, Leung T, Yuen J. Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. Cancer 1995;75:1663-1668.
21. Mora J, Gascon N, Tabernero JM, Germa JR, Gonzalez F. Alpha-fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. Eur J Cancer 1995; 31A:2239-2242.
22. Cole LA. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem 1997;43:2233-2243.
23. Karanda A, Cole LA. Polypeptide nicks cause erroneous results in assays of human chorionic gonadotropin free beta-subunit. Clin Chem 1992;38:26-33.
24. O'Reilly SM, Rustin GJS. Mismanagement of choriocarcinoma due to false low hCG measurement. Int J Gynecol Cancer 1993;3:186-188.
25. Sturgeon C, Dati F, Duffy MJ, Hasholzner U, Klapdor R, Lamerz R, Malbohan I, Martin M, Troonen H, Van Dahlen A, Zwirner M. Quality requirements and control: EGTM Recommendations. Anticancer Res 1999;19:2791-2794.
26. Horwich A, Peckham MJ. Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol 1984;20:1463-1470.
27. Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 1996;155:587-589.
28. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441-448.
29. International Germ Cell Cancer Collaborative Group: International germ cell cancer consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
30. Toner G, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990;50:5904-5910.
31. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Serum tumor marker decline is an early predictor of treatement outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994;73:2520-2526.
32. Stevens MJ, Norman AR, Dearnaley PD, Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995;13:87-92.
33. de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 1997;75 432-435.
34. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998;78:1350-1355.
35. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177-1187.
36. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998;16:1294-1297.
37. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-2645.
38. De Bruijn HW, Sleijfer DT, Schraffordt Koops H, Suurmeijer AJ, Marrink J, Ockhuizen T. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors. Cancer 1985;55:829-835.
39. Trigo JM, Tabernero JM, Paz-Ares L, Garc-Llano JL, Mora J, Lianes P, Esteban E, Salazar R, Lopez-Lopez JJ, Cort-Funes H. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88:162-168.